Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oligopeptide of specifically combined prostate cancers and application of oligopeptide

A prostate cancer and prostate technology, applied in the field of protein peptides, can solve the problem of few reports on prostate cancer targeting ligands, and achieve the effects of small molecular weight, good tissue penetration, and high diagnostic sensitivity

Active Publication Date: 2014-07-02
汉恒生物科技(上海)有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, this technology has successfully screened targeting peptides for liver cancer, colon cancer, breast cancer and other human tumors, but there are few reports on screening ligands for prostate cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oligopeptide of specifically combined prostate cancers and application of oligopeptide
  • Oligopeptide of specifically combined prostate cancers and application of oligopeptide
  • Oligopeptide of specifically combined prostate cancers and application of oligopeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 Screening of Prostate Cancer-Specific Binding Polypeptides

[0020] In this embodiment, a phage display random 12-peptide library is used to subtractively screen the polypeptides that specifically bind to prostate cancer cells, and the specific steps are as follows:

[0021] After the human prostate cancer cells LNCaP and PC3 were digested with trypsin, the cell density was adjusted, seeded in a culture dish pre-coated with polylysine, and the screening experiment was carried out when the cells grew to 80%-90% confluence.

[0022] Take the above LNCaP and PC3 cells, culture them with serum-free DMEM, add bovine serum albumin BSA to block, then add 20 μl phage peptide library, incubate for 1.5 h, pour to remove unbound phage, and shake upside down to remove residual solution. Rinse 4 times with washing solution 0.2% (v / v) TBST buffer, add non-specific buffer 0.2M glycine-hydrochloric acid (pH2.2) 2ml, suck out the eluate, add 250μl 5M Tris-HCl (pH9.0) to neutra...

Embodiment 2

[0027] The amplification of embodiment 2 phage

[0028] In Example 1, the phage obtained in each round of screening was diluted 100 times with LB medium, and 20 μl of the diluted phage was mixed with 200 μl of E. After the top layer of agar, quickly pour it on the LB solid plate containing IPTG / Xgal, treat it for 24 hours, count the number of plaques on the plate where the phage can grow, and then multiply this number by the dilution factor to get the plaque forming unit (pfu) per 10 μl phage Titer.

[0029] Enrichment of phage polypeptides specifically binding to prostate cancer cells: As shown in Table 1, the positive phage clones binding to LNCaP and PC3 increased the phage recovery rate by 1000 times after four rounds of selection.

[0030] Table 1 The recovery rate of positive phage after four rounds of screening

[0031] Screening times

Embodiment 3

[0032] Embodiment 3ELISA identification phage polypeptide

[0033] Identification of positive clones of phage polypeptides specifically binding to prostate cancer: In Example 1, after four consecutive rounds of subtractive screening of the phage peptide library, 20 phage clones were randomly selected, and the conventional methods in this field were used to preliminarily identify the phage clones against LNCaP. and PC3 affinity.

[0034] Divide LNCaP and PC3 by 1×10 4 The density per well was inoculated in a 96-well plate and placed in CO 2 After culturing in the incubator for 20 hours, the cells were treated with serum-free for 1 hour, washed, fixed with paraformaldehyde, washed once with PBS, treated with Triton X-100, blocked with PBS-BSA, added phage monoclonal, incubated for 2 hours; added HRP- Anti M13 antibody, incubate at 37°C for 1.5h; develop color with TMB, add an equal volume of 2N HCl or 1N H 2 SO 4 To terminate the reaction, the reaction solution in the microp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a series of polypeptides with characteristics of targeted prostate cancers, which are obtained by screening with a phage display peptide library technology. The combined polypeptides are high in specificity and can be used for general investigation of high-risk people with the prostate cancers, early clinical diagnosis of the prostate cancers and assessment of prostate cancer treatment effects.

Description

technical field [0001] The invention belongs to the technical field of protein polypeptides, and specifically relates to a series of short peptides that can specifically bind prostate cancer. Background technique [0002] Prostate cancer is one of the malignant tumors that seriously threaten the health of middle-aged and elderly men, and its incidence is increasing year by year, with a high mortality rate, ranking second only to lung cancer. For more than 50 years, androgen deprivation therapy has been the standard therapy for prostate cancer, however, most patients will eventually develop hormone-resistant prostate cancer (hormone refractory prostate cancer, HRPC). For HRPC, there is no effective therapy at present, and the existing treatment methods, including radiotherapy and chemotherapy, cannot prolong the patient's life for more than one year. Therefore, exploring new and effective methods for the treatment of prostate cancer has always been one of the important issue...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/08G01N33/68G01N33/574
CPCC07K7/08G01N33/56966G01N33/57434G01N33/68
Inventor 华国光
Owner 汉恒生物科技(上海)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com